Literature DB >> 21266008

Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin.

Lesley M Arnold1, Gergana Zlateva, Alesia Sadosky, Birol Emir, Ed Whalen.   

Abstract

OBJECTIVE: The objective of the study was to conduct an analysis of pooled data from pregabalin fibromyalgia clinical trials to determine which fibromyalgia symptom and function domains drive patient perception of improvement.
DESIGN: Data from three double-blind, placebo-controlled trials of pregabalin in fibromyalgia patients were pooled for this analysis. Changes in independent variables, including the Medical Outcomes Study 36-item Short-Form Health Survey, Medical Outcomes Study-Sleep Scale, sleep quality score from the daily sleep diary, pain score from the daily pain diary, Fibromyalgia Impact Questionnaire, and Multidimensional Assessment of Fatigue were analyzed as predictors of outcome on the dependent variable, Patient Global Impression of Change (PGIC). Correlation analysis assessed relationships between the independent variables and PGIC. Cluster analysis identified dependencies among variables, and a shrinkage and selection method and stepwise logistic regression determined rank order of variables.
RESULTS: Improvement in PGIC at endpoint showed highest correlation with pain improvement, fatigue, sleep, and work and physical function (0.4 < r < 0.6). Cluster analysis identified three main clusters of symptoms at endpoint: mood (anxiety and depression), pain and sleep, and function and fatigue. Pain was ranked as the most important outcome explaining variability in PGIC, followed by fatigue and sleep.
CONCLUSIONS: Pain, fatigue, and sleep associate most strongly with improvement in PGIC. Physical- and work-related function also correlated with patients' overall assessment of improvement. These domains and their respective outcome measures can be used to improve assessment of patients' response to treatment. Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266008     DOI: 10.1111/j.1526-4637.2010.01047.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  5 in total

1.  Development of responder definitions for fibromyalgia clinical trials.

Authors:  Lesley M Arnold; David A Williams; James I Hudson; Susan A Martin; Daniel J Clauw; Leslie J Crofford; Fujun Wang; Birol Emir; Chinglin Lai; Rong Zablocki; Philip J Mease
Journal:  Arthritis Rheum       Date:  2012-03

2.  Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.

Authors:  Philip J Mease; Daniel J Clauw; Robin Christensen; Leslie J Crofford; R Michael Gendreau; Susan A Martin; Lee S Simon; Vibeke Strand; David A Williams; Lesley M Arnold
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

3.  Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia.

Authors:  Lesley M Arnold; Joseph C Cappelleri; Andrew Clair; Elizabeth T Masters
Journal:  Pain Ther       Date:  2013-04-18

4.  Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial.

Authors:  Dana L Dailey; Carol G T Vance; Barbara A Rakel; M Bridget Zimmerman; Jennie Embree; Ericka N Merriwether; Katharine M Geasland; Ruth Chimenti; Jon M Williams; Meenakshi Golchha; Leslie J Crofford; Kathleen A Sluka
Journal:  Arthritis Rheumatol       Date:  2020-03-18       Impact factor: 15.483

5.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.